Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions
Дата публикации: 23-06-2026 07:06:00

Findings from the WU-KONG28 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC0530-06-2026
2No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection0522-06-2026
3Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma5730-06-2026
4Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma0509-07-2026
5New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer5702-07-2026
6New targeted therapy shows promising early results in advanced pancreatic cancer2705-07-2026
7FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
8Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer7801-07-2026
9EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
10EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.esmo.org.